Drug Trial Radar · NCT02333071
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Last checked: Nov 19, 2026Latest source record: Apr 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
723
Actual
Start
Dec 2014
Primary completion
Jul 2016
Study completion Jun 30, 2017
Sponsor
- Lead sponsor
- Palatin Technologies, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.
Conditions
- Hypoactive Sexual Desire Disorder
Interventions
BremelanotideDrug
A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
- Efficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
Locations
91 sites in 2 countries. Site status is shown where the registry gives one.
Palatin Clinical Site 121
Birmingham, Alabama
Palatin Clinical Site 110
Huntsville, Alabama
Palatin Clinical Site 106
Mobile, Alabama
Palatin Clinical Site 149
Scottsdale, Arizona
Palatin Clinical Site 157
Tucson, Arizona
Palatin Clinical Site 166
Little Rock, Arkansas
Palatin Clinical Site 102
National City, California
Palatin Clinical Site 164
Oceanside, California
Palatin Clinical Site 152
Orange, California
Palatin Clinical Site 188
Sacramento, California
Palatin Clinical Site 141
San Diego, California
Palatin Clinical Site 187
Walnut Creek, California
Palatin Clinical Site 160
Centennial, Colorado
Palatin Clinical Site 185
Colorado Springs, Colorado
Palatin Clinical Site 130
Bradenton, Florida
Palatin Clinical Site 128
Hollywood, Florida
Palatin Clinical Site 134
Jacksonville, Florida
Palatin Clinical Site 108
Melbourne, Florida
Palatin Clinical Site 105
Orlando, Florida
Palatin Clinical Site 131
South Miami, Florida
Palatin Clinical Site 144
St. Petersburg, Florida
Palatin Clinical Site 101
West Palm Beach, Florida
Palatin Clinical Site 116
Decatur, Georgia
Palatin Clinical Site 142
Savannah, Georgia
Palatin Clinical Site 171
Meridian, Idaho
Palatin Clinical Site 179
Evansville, Indiana
Palatin Clinical Site 165
Lafayette, Indiana
Palatin Clinical Site 154
Mishawaka, Indiana
Palatin Clinical Site 184
West Des Moines, Iowa
Palatin Clinical Site 155
Overland Park, Kansas
Palatin Clinical Site 104
Wichita, Kansas
Palatin Clinical Site 191
Louisville, Kentucky
Palatin Clinical Site 194
Eunice, Louisiana
Palatin Clinical Site 186
New Orleans, Louisiana
Palatin Clinical Site 183
Bangor, Maine
Palatin Clinical Site 159
Annapolis, Maryland
Palatin Clinical Site 119
Boston, Massachusetts
Palatin Clinical Site 126
Watertown, Massachusetts
Palatin Clinical Site 163
Bingham Farms, Michigan
Palatin Clinical Site 181
Rochester, Michigan
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.